2025年生物追踪器数据监测医疗ASCO周末更新_106页_2mb

The Biomedtracker ASCO Weekend 2025 report covers 170+ oncology trial updates from the American Cancer Society Annual Meeting, focusing on front-line approvals and data across key indications like bladder, breast, gastric, lung, and others. Here are key highlights:

Key Highlights:

• Bladder Cancer: Opdivo/Yervoy combo demonstrated superior progression-free survival (PFS) and objective response rates (ORR) vs. chemotherapy in cisplatin-ineligible patients, though failed to meet primary OS endpoints in some trials. Padcev+Keytruda established itself as standard 1L therapy due to improved PFS and ORR in platinum-ineligible patients.
• **Gastric Cancer:**Sacituzumab govitecan (Trodelvy) + Pembrolizumab showed a significant PFS improvement (HR 0.65, median PFS 11.0 months) in second-line treatment of PD-L1+ advanced gastric cancer, setting a new standard.
• **NSCLC:**Imfinzi+chemo combo (FLOT) improved EFS by 48% (HR 0.61) vs. chemo alone in resectable NSCLC, while Krazati+Keytruda achieved ORR upgrades in KRAS G12C-mutant non-small cell lung cancer. Treatments like Trodelvy showed durable PFS benefits when combined with ICIs.
• **Breast Cancer:**Trodelvy+Pembrolizumab became the new standard of care in TNBC; Scemblix+chemo improved outcomes in HR+/HER2- advanced disease.
• **Brain Cancer:**INB-200 demonstrated OS trends and improved PFS in recurrent glioblastoma patients. IN8bio's dual CD19/CD20 CAR-T candidate achieved an 87% ORR in DLBCL.
• **General Trends:**Key developments include accelerated approvals for ctDNA-guided resistance management (e.g., ROR1 inhibitors), combination optimization with ADCs/ICIs (e.g., Trodelvy, Bavencio), and explorations of novel targets like AKT inhibition in CLL.

Challenges & Unmet Needs:

• Insufficient durable responses in chemo-refractory settings remain an issue despite ICI combination efficacy.
• Balancing clinical benefit with toxicity concerns (e.g., ITC kinase inhibitors, dual CAR-T regimens).
  -Building pathways for early biomarker-driven treatments (ctDNA resistance, KRAS inhibitors).

The report underscores a clear shift toward combination strategies and liquid biopsy-guided approaches to overcome resistance and prolong survival across solid tumors.